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Summary
Objective: Insulin resistance develops prior to the onset of overt type 2 diabetes,
making its early detection vital. Direct accurate evaluation is currently only possible
with complex examinations like the stable isotope-based hyperinsulinemic
euglycemic clamp (HIEC). Metabolomic profiling enables the detection of thousands
of plasma metabolites, providing a tool to identify novel biomarkers in human
obesity.
Design: Liquid chromatography mass spectrometry–based untargeted plasma met-
abolomics was applied in 60 participants with obesity with a large range of peripheral
insulin sensitivity as determined via a two-step HIEC with stable isotopes [6,6-2H2]
glucose and [1,1,2,3,3-2H5]glycerol. This additionally enabled measuring insulin-
regulated lipolysis, which combined with metabolomics, to the knowledge of this
research group, has not been reported on before.
Results: Several plasma metabolites were identified that significantly correlated with
glucose and lipid fluxes, led by plasma (gamma-glutamyl)citrulline, followed by beta-
ine, beta-cryptoxanthin, fructosyllysine, octanylcarnitine, sphingomyelin (d18:0/18:0,
d19:0/17:0) and thyroxine. Subsequent machine learning analysis showed that a
panel of these metabolites derived from a number of metabolic pathways may be
used to predict insulin resistance, dominated by non-essential amino acid citrulline
and its metabolite gamma-glutamylcitrulline.
Conclusion: This approach revealed a number of plasma metabolites that correlated
reasonably well with glycemic and lipolytic flux parameters, measured using gold
standard techniques. These metabolites may be used to predict the rate of glucose
disposal in humans with obesity to a similar extend as HOMA, thus providing poten-
tial novel biomarkers for insulin resistance.
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1 | INTRODUCTION
Obesity is often accompanied by metabolic disorders such as dys-
lipidemia and insulin resistance, both part of the metabolic syndrome,
which in turn is a major risk factor for type 2 diabetes (T2DM), cardio-
vascular pathology, non-alcoholic fatty liver disease and different
types of cancer.1,2 Insulin resistance develops prior to the beginning
of overt T2DM, making its early detection of vital clinical importance.
However, direct accurate evaluation of insulin resistance in relation to
fasting insulin and (compensatory) hyperinsulinemia is currently only
possible using complex, invasive and time-consuming examinations
such as the two-step stable isotope based hyperinsulinemic
euglycemic clamp (HIEC), a method which is regarded as the gold
standard. This method also allows for distinguishing between hepatic
and peripheral insulin sensitivity (Rd).
An interesting developing research field in this respect is
untargeted metabolic profiling, which enables the detection of in prin-
ciple thousands of plasma metabolites.3 These metabolites are prod-
ucts that reflect levels of cellular (dys)function. As they are influenced
by both environmental (dietary) and biological (genetic) factors,
plasma metabolites may provide insight into the balance of genotype
and phenotype of T2DM. Moreover, due to the unbiased nature that
characterizes metabolomic platforms, they can provide a tool to unveil
novel underlying mechanisms of insulin resistance, metabolic syn-
drome and its dire consequences in humans with obesity.
Branched chain amino acids and other plasma metabolites such as
glycerol, α-hydroxybutyrate and mannitol4 are increased in patients
with T2DM and might serve as potential novel biomarkers for insulin
resistance.5-8 However, there is a lack of studies in humans with met-
abolic syndrome that correlate novel metabolites with the gold stan-
dard measurement of glucose fluxes in the HIEC and, to the
knowledge of this research group, no studies are available that com-
bine both parameters. Consequently, this results in a lack of novel bio-
markers able to predict aberrant glycemic control in patients with
insulin resistance in an earlier phase.9 A recent systematic review
evaluated metabolite markers identified using high-throughput met-
abolomics techniques in patients cohorts with prediabetes and T2DM;
however, in these patients, insulin resistance was determined via sim-
ple or indirect tests such as the oral glucose test, but never by HIEC.8
Alternative methods have been developed such as the Homeostatic
Model Assessment (HOMA) and Quantitative insulin sensitivity check
index (QUICKI), which calculate insulin resistance fairly accurately
using fasting insulin and glucose concentrations. Nevertheless, as sur-
rogate indirect methods, they have their limitations compared with
the direct clamp method and are still unable to detect early stages of
aberrant glucose metabolism and insulin resistance.10
Thus, in order to determine plasma metabolites, which are able to
predict insulin resistance in an earlier stage and explore their interac-
tion with glucose and lipid fluxes in the fasting state, liquid chroma-
tography mass spectrometry (LC-MS)–based untargeted plasma
metabolomics (Metabolon) was applied in 60 participants with obesity
with an extensive range of Rd as determined by a two-step HIEC with
stable isotopes [6,6-2H2]glucose and [1,1,2,3,3-
2H5]glycerol, which
also allowed for the measurement of insulin regulated lipolysis (Ra).
Other metabolic parameters determined were hepatic insulin sensitiv-
ity, as measured via suppression of endogenous glucose production
(EGP), and resting energy expenditure (REE), measured by indirect cal-
orimetry, as well as dietary intake. This study shows that a panel of
plasma metabolites could be used to predict (peripheral) insulin resis-
tance as a substitute for the invasive laborious HIEC. Indeed, several
metabolites were identified that significantly correlated with glucose
and lipid fluxes, led by plasma citrulline and gamma-glutamylcitrulline,
followed by plasma betaine, beta-cryptoxanthin, fructosyllysine,
octanylcarnitine, sphingomyelin (d18:0/18:0, d19:0/17:0) and
thyroxine.
2 | METHODS
2.1 | Study participants
Male (n=30) and female participants (n=30) with obesity, defined as
body mass index (BMI) ≥ 30 kg m−2, were recruited via local advertise-
ments. Participants were excluded in case of a primary lipid disorder,
childhood onset obesity (due to higher risk of developing T2DM also
based on more genetic predisposition), use of exogenous insulin, all
medical and psychiatric conditions except for obesity related diseases,
coagulation disorders, uncontrolled hypertension, renal insufficiency,
substance abuse (nicotine or drugs, alcohol >2 units day−1), pregnancy
and breastfeeding. All participants provided written informed consent,
and all study procedures were approved by the Academic Medical
Center IRB and conducted in accordance with the Declaration of
Helsinki.
2.2 | Study design
Following informed consent and screening, participants visited the
clinical research unit after an overnight fast. Participants were
instructed to record food intake and dietary habits online (mijn.
voedingscentrum.nl/nl/eetmeter) the week before the study visit.
During the study day, blood samples were drawn followed by the
two-step HIEC during which glucose and lipid fluxes were determined
as well as REE, as described below.
3 | MEASUREMENTS
3.1 | Two-step HIEC and REE
REE was measured in all participants during the basal state of the
HIEC by indirect calorimetry. During 20 minutes, oxygen consump-
tion and CO2 production were measured continuously using a venti-
lated hoodsystem (Vmax Encore 29; SensorMedics, Anaheim, CA).
REE was then calculated from oxygen consumption and carbon diox-
ide production.11 To measure insulin resistance, a two-step HIEC
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was performed.12 After an overnight, fast participants visited the
hospital where they received two catheters in the peripheral veins
of both arms. One catheter was used to infuse the [6,6-2H2]glucose
and [1,1,2,3,3-2H5]glycerol (99% enriched; Cambridge Isotopes,
Andover, MA, USA), together with 20% glucose enriched with 1%
[6,6-2H2]glucose and insulin (Actrapid; Novo Nordisk Farma, Alphen
aan de Rijn, The Netherlands). The other catheter was used for sam-
pling blood, which was arterialized by heating the arm with a
heated-hand box at 57C. At 2 hours before starting the clamp
(t=−2 h), a primed continuous infusion of both [6,6-2H2]glucose and
[1,1,2,3,3-2H5]glycerol was started and continued until the end of
the experiment. After 2 hours (t=0), infusion of insulin was started
at a rate of 20 mUm−2 (body surface area)minute−1. Plasma glucose
was measured every 10 minutes using a glucose analyser (YSI 2300
Stat Plus Glucose Lactate Analyzer, YSI Life Sciences, Yellow Springs,
Ohio). In order to keep plasma glucose at 5 mmolL−1, 20% glucose
enriched with 1% [6,6-2H2]glucose was infused at a variable rate.
Insulin infusion was increased after 2 hours of insulin infusion
(t=2 h) to 60 mUm−2minute−1. At t=0, 2 and 4 hours, five blood
samples were taken to assess glucose and glycerol enrichments.
Rates of disposal (Rd) of glucose and rates of appearance (Ra) of
glycerol were calculated using the modified forms of the Steele
equations for (non)steady state measurements as described
previously.13
3.2 | Biochemistry
Fasting glucose (Hitachi), insulin (Diagnostic products) and C-reactive
protein (CRP, Roche, Switzerland) were determined in fasted plasma
samples. Total cholesterol, high-density lipoprotein cholesterol (HDLc)
and triglycerides (TG) were determined in EDTA-containing plasma
using commercially available enzymatic assays (Randox, Antrim, UK
and DiaSys). All analyses were performed using a Selectra auto-
analyser (Sopachem, The Netherlands). Low-density lipoprotein cho-
lesterol (LDLc) was calculated using the Friedewald formula. Insulin
was determined on an Immulite 2000 system (Diagnostic Products,
Los Angeles, CA, USA). As described previously, plasma analyses were
performed,14 [6,6-2H2] glucose enrichment was measured
15 and
[1,1,2,3,3-2H5]glycerol determined.
16
3.3 | Metabolomic profiling
As mentioned above, EDTA plasma samples were taken from partici-
pants before the clamp in the fasting state. Plasma metabolite
untargeted profiling analysis was carried out on plasma by Metabolon
(Durham, NC), using ultrahigh-performance liquid chromatography
coupled to tandem mass spectrometry, as previously described.17 This
method allowed for the study of 934 annotated plasma metabolites.
Raw data were normalized to account for interday measurement
differences. Then, each biochemical was rescaled to set the median
equal to 1. Missing values, generally due to the sample measurement
falling below the limit of detection, were then imputed with the mini-
mum observed value.
3.4 | Statistical analysis
Univariate (Spearman's rank) analyses were performed to determine
which metabolites correlated significantly (P-value of <.05) with Rd,
EGP suppression, REE and glycerol suppression of the included partic-
ipants. Subsequent multivariate linear regression was used to correct
for age and BMI.
3.5 | Machine learning to discern relative
importance of plasma metabolites with Rd
In the multivariate analysis, the model was a gradient boosting
regressor,18 which was optimized for R2, taking the previously
analysed metabolic biomarkers which were correlated with Rd as the
input and the Rd derived from the HIEC as the output value. To avoid
overfitting, a tenfold stratified cross validation was performed over
the training partition of the data (80%), while the remaining data
(20%) were used as the test dataset. The identification of the most
predictive plasma biomarkers was achieved through the use of permu-
tation importance. First, a predictive model was build using the com-
plete set of the metabolites. This led to a baseline R2 predictive
performance of the model. Afterwards, the values of one metabolite
were shuffled for all participants in the database and the predictive
performance of the model was recomputed. The difference between
the baseline performance of the model and the one computed on the
shuffled dataset gave the predictive power of this particular metabo-
lite. This procedure was then repeated for all the metabolites in the
database, thus obtaining the final ranking. Moreover, a rigorous stabil-
ity selection procedure was conducted to ensure the reliability and
robustness of these biomarker signatures. This was repeated 20 times,
and the R2 scores were computed each time and averaged for the
final test R2 score. The software tools used were Python v. 3.7
(www.python.org), with the packages Numpy, Scipy and Scikit-learn
for machine learning models. To generate the visualizations, the pack-
ages used were matplotlib and plotly.
4 | RESULTS
4.1 | Baseline characteristics
In total, 60 participants were included with obesity (BMI ≥ 30 kg m−2),
of which 30 male and 30 female, aged 51 ± 12 (mean ± SD) years with
a BMI of 39 [34-44] (median [interquartile range]) kg m−2. Metabolic
baseline characteristics included a fasting glucose of 5.3 ± 0.8 mmol
L−1, fasting insulin of 115 ± 56 pmol L−1 and HOMA-IR of 3.9 ± 2.1,
while total cholesterol was 5.1 ± 1.2 mmol L−1 with an LDL of 3.2 ±
1.1 mmol L−1 and HDL of 1.3 ± 0.3 mmol L−1. Dietary data included a
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caloric intake of 1,670 ± 394 kcal per day, with an intake of 66 ±
20, 79 ± 18, 16 ± 5 and 170 ± 46 g of fat, protein, fibre and carbohy-
drate respectively.
4.2 | Glucose and lipid fluxes
Insulin sensitivity was determined in each subject via a two-step
HIEC. The use of [6,6-2H2]glucose infusion enabled the assessment of
the ability of insulin to suppress EGP (EGP suppression, a marker of
hepatic insulin sensitivity) and whole-body glucose rate of disposal
(Rd, a marker of peripheral insulin sensitivity). The measured Rd values
ranged from high to low showing a spectrum of insulin sensitivity
from insulin sensitive (maximum 57.4 μmol kg−1 minute−1) to insulin
resistant (minimum 11.9 μmol kg−1 minute−1), with a mean of 31.8 ±
12.7 μmol kg−1 minute−1. EGP suppression ranged from 47 to 100 %
with a mean of 75.7 ± 14 %. Other metabolic parameters measured
during the clamp were REE via calorimetry, with a mean of 1,885 ±
376 kcal day−1, and insulin-regulated lipolysis using [1,1,2,3,3-2H5]
glycerol to determine suppression of glycerol rate of appearance
(Ra, a measure of adipose tissue insulin sensitivity) with a mean of
56.2 ± 14.3 %. As previously described, insulin resistance was defined
as an Rd value of <37.3 μmol kg−1 minute−1.19 In the current study,
population 71.7 % of all participants had an Rd lower than 37.3 and
were therefore considered insulin resistant (Figure 1).
4.3 | Correlations of metabolic parameters with
plasma metabolites
As expected, fasting plasma insulin levels and HOMA values corre-
lated significantly with Rd (Figures 2A and 2B). Moreover, other uni-
variate analyses revealed significantly correlated plasma metabolites
with peripheral insulin sensitivity (Rd), hepatic insulin sensitivity
(EGP suppression), lipolysis (Ra), fasting insulin, HOMA and REE. Sub-
sequent multivariate regression analyses were used to correct for the
influence of age and BMI. Additionally, correlating plasma metabolites
were tested for predictive ability of Rd. Seventeen plasma metabolites
were found that significantly correlated with Rd, of which 12 corre-
lated with 1 or more other fluxes and/or were found to be predictive
of Rd. This included 1-palmitoyl-2-stearoyl-GPC (16:0/18:0), beta-cry-
ptoxanthin, betaine, fructosyllysine, glycosyl-N-(2-hydroxynervonoyl)-
sphingosine (d18:1/24:1(2OH)), octanylcarnitine, S-methylmethionine,
sphingomyelin (d18:0/18:0, d19:0/17:0), taurodeoxycholate 3-sulfate
and thyroxine (Table 1), whereas plasma gamma-glutamylcitrulline
(Figure 2C) and citrulline (Figure 2D) were most significantly corre-
lated with Rd. Moreover, 8 metabolites correlated significantly with
EGP suppression, of which 4 correlated with Rd, 2 also with the other
fluxes and 2 were predictive of Rd: beta-cryptoxanthin, betaine, fru-
ctosyllysine and taurodeoxycholate 3-sulfate (Table 2). Finally,
3 metabolites correlated significantly with REE of which beta-
cryptoxanthin correlated likewise with Rd and EGP suppression and
was found to be predictive of Rd (Table 3). With respect to lipid
fluxes, 20 metabolites correlated significantly with glycerol
suppression and 6 also correlated with Rd, other fluxes or were pre-
dictive of Rd: betaine, citrulline, gamma-glutamylcitrulline, glycosyl-N-
(2-hydroxynervonoyl)-sphingosine (d18:1/24:1(2OH)), sphingomyelin
(d18:0/18:0, d19:0/17:0) and thyroxine (Table 4).
4.4 | Combining plasma metabolites to predict
peripheral insulin sensitivity (Rd)
The 17 metabolites found to correlate significantly with Rd originate
from a number of different metabolic pathways. To investigate
whether a reliable prediction of Rd could be made from a combination
of these metabolites, a Gradient Boosting Machine Learning model
was used.18 The average R2 achieved by the model across the 20 per-
formed shuffles was 0.24. Figure 3 shows the top 10 metabolites that
were found to be most important in the Rd predictive model, headed
by plasma (gamma-glutamyl)citrulline levels, followed by HOMA and
fasting insulin levels.
5 | DISCUSSION
In this exploratory cross-sectional study (untargeted), metabolic profil-
ing was applied using fasting plasma samples of 60 participants with
obesity with an extensive range of peripheral insulin sensitivity,
revealing several metabolites that significantly correlated with glucose
and lipid fluxes as determined by stable isotope-based two-step HIEC.
Subsequent machine learning analysis showed that a combination of
these plasma metabolites may potentially be used to predict periph-
eral insulin resistance and sensitivity (Rd) with a reasonable accuracy.
Machine learning analysis on EGP and REE was not possible due to
the low number of correlating parameters. However, plasma gamma-
glutamylcitrulline emerged as the most important component in the
F IGURE 1 The distribution of peripheral insulin sensitivity (Rd) in
all 60 participants as measured via hyperinsulinemic euglycemic
clamp. The dashed line represents the cut-off point of an Rd of
37.3 μmol kg−1 minute−1, below of which is considered insulin
resistant
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machine learning model for Rd, followed by its precursor citrulline.
However, further (in vitro and in vivo) data are needed to strengthen
the biological evidence of the (gamma-glutamyl)citrulline pathway in
the pathophysiology of human insulin resistance and to prove the
value of this marker in its early detection.
Interestingly, citrulline and its metabolite gamma-
glutamylcitrulline have been already linked to insulin sensitivity of adi-
pose tissue (as determined by [1,1,2,3,3-2H5]glycerol). L-citrulline is a
non-essential amino acid20 with strong antioxidant properties and in
humans is involved in the urea cycle in the liver. The amino acid is not
secreted by the liver, but the amount found in plasma has been shown
to originate from production by enterocytes.21 Via its product argi-
nine, citrulline is important in the metabolism of nitric oxide (NO), a
signalling molecule critical for the cardiovascular system as a
vasodilatator.22 Oral supplementation of citrulline is more potent at
increasing serum arginine, and thus NO levels, than arginine itself due
to a first-pass extraction effect by arginase in the gastro-intestinal
tract, which does not affect citrulline.21 This has made it a promising
focus for research into new treatment modalities for metabolic and
cardiovascular-related diseases, as endothelial dysfunction, associated
with obesity-induced insulin resistance, hypertension and impaired
skeletal muscle metabolism have been linked to arginine and NO defi-
ciency in humans.23-25 Supporting the observation in this study of the
positive correlation between citrulline and glycerol suppression, ani-
mal studies have shown promising results of citrulline supplementa-
tion on lipolysis, reducing adipose tissue.26
F IGURE 2 Correlation plots of most important plasma markers with peripheral insulin sensitivity (Rd). The figures show the correlation of
fasting plasma insulin (A), HOMA (B), gamma-glutamylcitrulline (C) and citrulline (D with peripheral insulin sensitivity Rd as measured by stable
isotope based hyperinsulinemic euglycemic clampin 60 participants
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TABLE 1 Correlations between fasting plasma metabolite and peripheral insulin sensitivity (Rd)
Metabolite Pathway P rho r
Match
Other Flux
Relative Importance for
Predicting Rd, %
1-palmitoyl-2-linleoyl-GPC (16:0/18:2) Phospholipid metabolism .03 −0.27 −0.24
1-palmitoyl-2-stearoyl-GPC
(16:0/18:0)
Phospholipid metabolism .04 0.46 0.48 21
Beta-cryptoxanthin Vitamin A metabolism .02 0.39 0.46 EGP/REE 20
Betaine Glycine, serine and threonine
metabolism
.01 0.39 0.39 EGP/Ra 19
Citrulline Urea cycle; arginine and proline
metabolism
.01 0.44 0.42 Ra 77
Cortisol Corticosteroid .01 −0.30 −0.31
Decanoylcarnitine (C10) Fatty acid metabolism (acyl
carnitine, medium chain)
.01 −0.36 −0.36
Fructosyllysine Lysine metabolism .01 −0.37 −0.38 EGP
Gamma-glutamylcitrulline Citrulline metabolism .03 0.40 0.37 Ra 100
Glyco-beta-muricholate Primary bile acid metabolism .03 −0.31 −0.27
Glycodeoxycholate 3-sulfate Secondary bile acid metabolism .05 −0.34 −0.34
Glycosyl-N-(2-hydroxynervonoyl)-
sphingosine (d18:1/24:1(2OH))
Glycolipid metabolism .00 −0.37 −0.35 Ra
Octanoylcarnitine (C8) Fatty acid metabolism (acyl
carnitine, medium chain)
.02 −0.40 −0.15 11
S-methylmethionine Methionine, cysteine, SAM and
taurine metabolism
.04 0.30 0.32 12
Sphingomyelin (d18:0/18:0,
d19:0/17:0)
Phospholipid metabolism .02 −0.26 −0.25 Ra 25
Taurodeoxychol 3-sulfate Secondary bile acid metabolism .03 −0.39 −0.39 EGP
Thyroxine Thyroid .03 −0.40 −0.41 Ra
Note. Shown are significant (P<.05) Spearman's correlations between metabolites and Rd after correction with multivariate linear regression for age and
BMI. Metabolites were considered relevant according to match with other flux, relative importance for predicting Rd via machine learning model and/or
availability of literature.
Abbreviations: EGP: endogenous glucose production (hepatic insulin sensitivity); Ra: rate of appearance (glycerol suppression); Rd: rate of disappearance
(peripheral insulin sensitivity); REE: resting energy expenditure.
TABLE 2 Correlations between fasting plasma metabolite and hepatic insulin sensitivity (EGP suppression)
Metabolite Pathway P rho r
Match
Other Flux
Relative Importance for
Predicting Rd, %
3b-hydroxy-5-cholenoic acid Secondary bile acid metabolism .02 −0.27 −0.19
Beta-cryptoxanthin Vitamin A metabolism .02 0.35 0.28 Rd/REE 20
Betaine Glycine, serine and threonine metabolism .01 0.28 0.25 Rd/Ra 19
Docosatrienoate (22:3n3) Fatty acid metabolism .05 −0.36 −0.35
Etiocholanolone glucuronide Androgenic steroids .04 −0.31 −0.33
Fructosyllysine Lysine metabolism .01 −0.37 −0.36 Rd
Lysine Lysine metabolism .04 −0.29 −0.32
Taurodeoxychol 3-sulfate Secondary bile acid metabolism .03 −0.27 −0.10 Rd
Note. Shown are significant (P<.05) Spearman's correlations between metabolites and EGP suppression after correction with multivariate linear regression
for age and BMI. Metabolites were considered relevant according to match with other flux, relative importance for predicting Rd via machine learning
model and/or availability of literature.
Abbreviations: BMI: body mass index; EGP: endogenous glucose production.
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The medium-chain acylcarnitines, decanoylcarnitine and
octanoylcarnitine were both negatively associated with insulin sensi-
tivity, and especially octanoylcarnitine was found to be predictive of
Rd (Figure 3). There is growing evidence of plasma acylcarnitines as
potential biomarkers for insulin resistance.27 In study participants with
T2DM, octanoylcarnitine and decanoylcarnitine were both increased
compared with controls.28 A substrate overload of fatty acids may
result in incomplete long-chain fatty acid β-oxidation, allowing for
accumulation of acylcarnitines which via pro-inflammatory NFkB-
associated pathways impair insulin action, thus promoting insulin
resistance.27 In participants with obesity and T2DM, in whom the
degree of insulin resistance was measured via a HIEC similar to this
study, plasma acylcarnitines were found to be significantly elevated,29
supporting the current observations.
TABLE 3 Correlations between fasting plasma metabolite and resting energy expenditure (REE)
Metabolite Pathway rho P r
Match
Other Flux
Relative Importance for
Predicting Rd, %
1-docosahexaenoylglycerol (22:6) Fatty acid metabolism −0.43 .01 −0.44
Beta-cryptoxanthin Vitamin A metabolism −0.43 .02 −0.31 Rd/EGP 20
Docosahexaenoate (DHA; 22:6n3) Fatty acid metabolism −0.44 .03 −0.46
Note. Shown are significant (P<.05) Spearman's correlations between metabolites and REE after correction with multivariate linear regression for age and
BMI. Metabolites were considered relevant according to match with other flux, relative importance for predicting Rd via machine learning model and/or
availability of literature.
Abbreviation: BMI: body mass index.
TABLE 4 Correlations between fasting plasma metabolite and glycerol suppression (Ra)
Metabolite Pathway P rho r
Match
Other Flux
Relative Importance for
Predicting Rd, %
1-linoleoyl-GPI* (18:2)* Phospholipid metabolism .00 −0.45 −0.60
1-oleoyl-GPI (18:1) Phospholipid metabolism .03 −0,32 −0.33
1-palmitoleoyl-2-linolenoyl-GPC (16:1/18:3)* Phospholipid metabolism .01 −0,31 -0.38
1-palmitoyl-2-linoleoyl-GPI (16:0/18:2) Phospholipid metabolism .04 −0,34 −0.33
1-stearoyl-2-linoleoyl-GPI (18:0/18:2) Phospholipid metabolism .01 −0,30 −0.37
3-hydroxyoleate Fatty acid metabolism .03 −0,26 −0.21
5alpha-androstan-3alpha,17beta-diol
monosulfate (2)
Androgenic steroids .02 0.40 0.31
Betaine Glycine, serine and
threonine metabolism
.01 0.40 0.39 Rd/EGP 19
Biliverdin Hemoglobin and porphyrin
metabolism
.03 0.29 0.33
Citrulline Urea cycle; arginine and
proline metabolism
.01 0.39 0.42 Rd 77
Epiandrosterone sulfate Androgenic steroids .04 0.28 0.05
Gamma-glutamylcitrulline Citrulline metabolism .01 0.40 0.41 Rd 100
Glycosyl-N-(2-hydroxynervonoyl)-Sphingosine
(d18:1/24:1(2OH))
Glycolipid metabolism .04 −0.33 −0.28 Rd
Guanidinoacetate Creatine metabolism .04 0.35 0.33
N-stearoyl-sphinganine (d18:0/18:0) Ceramide metabolism .03 −0,36 −0.28
Sphingomyelin (d18:0/18:0, d19:0/17:0) Phospholipid metabolism .01 −0,36 −0.33 Rd 25
Sphingomyelin (d18:1/18:1, d18:2/18:0) Phospholipid metabolism .02 −0,35 −0.32
Sphingomyelin (d18:1/20:2, d18:2/20:1,
d16:1/22:2)
Phospholipid metabolism .03 −0,28 −0.27
Sphingomyelin (d18:2/16:0, d18:1/16:1) Phospholipid metabolism .04 −0,31 −0.37
Thyroxine Thyroid .02 −0.34 −0.40 Rd
Note. Shown are significant (P<.05) Spearman's correlations between metabolites and Ra after correction with multivariate linear regression for age and
BMI. Metabolites were considered relevant according to match with other flux, relative importance for predicting Rd via machine learning model and/or
availability of literature.
Abbreviation: BMI: body mass index.
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Previous data were confirmed by our results, showing an inverse
significant association of plasma thyroxine levels with both peripheral
insulin sensitivity and adipose tissue insulin sensitivity.30 Both Rd and
Ra correlated negatively with sphingomyelin (d18:0/18:0,d19:0/17:0),
which is in accordance with previous data in patients with TDM2.31 In
line, a positive significant correlation was observed in this study
between plasma betaine and peripheral, hepatic and adipose tissue
insulin sensitivity. Betaine, also known as trimethylglycine, is an amino
acid, which is derived in the human body via dietary intake or via
mitochondrial oxidation of choline in kidney and liver (driving TMAO
production),32,33 and low betaine is significantly associated with key
criteria of metabolic syndrome.34,35 Moreover, in the current study,
the significant positive correlation was confirmed between plasma
beta-cryptoxanthin (β-CRX, a carotenoid) and peripheral and hepatic
insulin sensitivity.36,37 In obese animal models, β-CRX supplementa-
tion was inversely related to the risk of insulin resistance and liver
dysfunction, possibly mediated by inhibiting inflammatory gene
expression via the suppression of macrophages and of the signalling
of TNFα and gut-derived endotoxins (LPS).38-40 In humans, serum
β-CRX was likewise inversely related to insulin resistance41 and
decreased amount of visceral fat.42 Finally, the negative correlation
between fructosyllysine and both Rd and REE is in agreement with
other studies where the increase of this metabolite has been associ-
ated with obesity and insulin resistance in humans.43 Fructosyllysine
is a glyco-amino acid, also known as an early glycation product, which
is directly toxic to tissue and is a precursor of advanced glycation end
product formation.44,45
In conclusion, unravelling the interaction between plasma metab-
olites with glucose and lipid fluxes in persons with insulin resistance is
essential for our understanding of its pathophysiology and uncovering
yet unknown biomarkers and novel treatments. By combining
targeted plasma metabolomics with gold standard stable isotope-
based glucose and lipid fluxes in participants with obesity with an
extensive range of Rd, some well-known and some less known indica-
tors are provided for insulin resistance and a panel of these
metabolites is shown that may possibly be used to predict Rd to a sim-
ilar extend as fasting insulin and HOMA. Thus, plasma levels of
(gamma-glutamyl)citrulline may serve as a viable candidate for early
clinical diagnosis of insulin resistance (eg, in combination with HOMA)
when a stable isotope-based HIEC is not available.
There were some limitations to this study. First, only a markedly
obese population was studied and applicability of results to patients
who are less obese remains open. Also, based on the nature of
targeted metabolomics, plasma (gamma-glutamyl)citrulline levels were
measured in a semi-quantitative fashion. Finally, the sample size of
this pilot study was relatively small, but to the knowledge of this
research group, this is the only study that compares gold standard
stable isotope-based HIEC to plasma metabolites. Moreover, both
multivariate as well as machine learning approach analyses were
performed for non-linear multi-variate analysis of the metabolites in
various combinations (19), thus aiming to control for type 1 errors as
much as possible. Nevertheless, when further optimized, a biomarker
panel based on citrulline derivatives (presumably in combination with
HOMA) may replace the expensive and laborious HIEC to estimate
Rd. Future research aimed at validating these citrulline biomarkers in
larger prospective cohorts will have to confirm the findings reported
here, yet the identified plasma metabolites could have the potential to
enhance early identification of individual risks in patients at risk for
T2DM and monitoring of treatment response.
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